Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship

Mar 28, 2023

Announcing a further collaboration with the Frederick National Laboratory for Cancer Research

Dr Bill Eldridge, CEO of Isogenica, and Professor Dong-Hoon Jin, CEO of WMBIO, holding the MoU.



The relationship between Isogenica and the Frederick National Laboratory for Cancer Research (FNLCR) in Maryland USA, a government-owned, contractor-operated research and development facility currently operated by Leidos Biomedical Research, Inc., grows stronger as the start of two more projects are announced. The multi-project contract is aiming to develop molecules that can be used in clinical laboratory assays to measure biomarkers correlated with the molecular effectiveness of cancer immuno-oncology agents.

The team at Isogenica will develop and optimise their VHH (variable domain of a heavy chain) antibodies (or nanobodies, highly versatile small format antibodies), which are used to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases.

Alliances Manager at Isogenica, Claudia Fernandes reported, “Isogenica is excited to announce the start of two new projects with the FNLCR and the strengthening of our ongoing contractual relationship. We strive to offer the FNLCR unique VHH tools to achieve their health-oriented goals and further their strides in clinical research.”



Further Information

About Isogenica

Isogenica is a biotechnology company specializing in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific biotherapeutics. Drawing on more than 20 years at the forefront of antibody discovery and engineering, we have built a unique and proven engine for biotherapeutic development and a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.

For further information, visit  

About The Frederick National Laboratory for Cancer Research

The FNLCR works at the forefront of basic, translational, and clinical science with a focus on cancer, AIDS, and infectious disease. The scientists at the FNLCR are conducting a wide array of research; creating new technologies; and collaborating with governmental, industrial, and academic colleagues to efficiently address current public health questions in a novel and unique way. Their work has been instrumental within cancer, AIDS, diagnostics, immunology and many more fields of scientific research. They continue to push to better the lives of people across the world and provide clinical solutions to problems no-one has yet been able to.

Further information, visit: 


Business Development Team

T +44 1799 533 680